Innoviva Scores with Focus on Resistant Germs and Intensive Care Medicine

Innoviva holds interests in companies from the healthcare sector, with a particular focus on respiratory diseases. Originally, the company was closely associated with the pharmaceutical giant GlaxoSmithKline (GSK) and continues to benefit from royalty payments for jointly developed medications such as Breo Ellipta, which is used for the treatment of the lung disease COPD and asthma. In recent years, Innoviva has gradually evolved into a type of health holding company, strategically investing in smaller biotech firms with promising developments,...